Biotech News

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics (HOWL)Werewolf TherapeuticsConference / presentation

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Related news

HOWLWerewolf Therapeutics2026-11-09 13:30 EST

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Werewolf Therapeutics

Conditionally Activated Immunotherapy Company Werewolf Therapeutics develops immune-stimulating medicines engineered to activate preferentially in diseased tissue. Its strategy is intended to retain the antitumor potency of inflammatory cytokines while limiting systemic exposure and toxicity. PREDATOR Engineering Platform The proprietary...

Recent company news

Stock data

Close
0.99 USD
Market cap
20.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States